Mcm2 predicts recurrence hazard in stage Ta/T1 bladder cancer more accurately than CK20, Ki67 and histological grade

por Burger, M, Denzinger, S, Hartmann, A, Wieland, W-F, Stoehr, R, Obermann, E C
Publicado 2007

Adjuvant treatment with interleukin-2- and interferon-alpha2a-based chemoimmunotherapy in renal cell carcinoma post tumour nephrectomy: Results of a prospectively randomised Trial...

por Atzpodien, J, Schmitt, E, Gertenbach, U, Fornara, P, Heynemann, H, Maskow, A, Ecke, M, Wöltjen, H H, Jentsch, H, Wieland, W, Wandert, T, Reitz, M
Publicado 2005

Biomodulatory Treatment of Patients with Castration-Resistant Prostate Cancer: A Phase II Study of Imatinib with Pioglitazone, Etoricoxib, Dexamethasone and Low-Dose Treosulfan

por Vogelhuber, M., Feyerabend, S., Stenzl, A., Suedhoff, T., Schulze, M., Huebner, J., Oberneder, R., Wieland, W., Mueller, S., Eichhorn, F., Heinzer, H., Schmidt, K., Baier, M., Ruebel, A., Birkholz, K., Bakhshandeh-Bath, A., Andreesen, R., Herr, W., Reichle, A.
Publicado 2014